Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
About this item
Full title
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In this trial, daclizumab high-yield process (a monoclonal antibody that binds to CD25 and modulates interleukin-2 signaling) was more effective than interferon beta-1a in patients with relapsing–remitting multiple sclerosis. Infection and rash were more common with daclizumab.
Daclizumab is a humanized monoclonal antibody that binds to the alph...
Alternative Titles
Full title
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1721354552
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1721354552
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1501481
